-
July 19, 2022 Compass Pathways Appoints a New CEOGeorge Goldsmith will be replaced as Compass Pathways CEO. Is this good or bad news?
-
July 11, 2022 The Battle for Psychedelic PatentsPsychedelic companies rely on novel patents to boost their value, but many players in the...
-
July 6, 2022 MindMed CEO AMA: 18-MC Patent, Digital Tech, LSD Trials and More! (MNMD / MMED)In today's episode, James from PSYCBiz interviews Robert Barrow, CEO of Mindmed (NASDAQ: MNMD) (NEO:...
-
July 1, 2022 Meet the Next-Gen Psychedelic Treating Alcoholism | Is this the Future of Addiction Treatment?In today’s episode of PsycBiz, James —the Psychedelic Investor— sits down with Mark Haden, VP...
-
July 1, 2022 Psychedelic Business Spotlight – July 1This week in psychedelic stock news: MindMed downplays delisiting fears; Red Light Holland teams with...
-
July 1, 2022 MindMed Reassures Investors over Nasdaq Delisting FearsIn a Reddit AMA, MindMed CEO Robert Barrow says Nasdaq delisting is not “a risk...
-
June 28, 2022 Can Wearable Technology Help Alleviate Stress?Can wearable technology help alleviate stress? Apollo Neuro's new wearable shows amazing promise
-
June 24, 2022 This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!This week in psychedelic stock news, there are big patent developments for Compass, MindMed and...
-
June 24, 2022 Compass Pathways Psilocybin Patent UpheldCompass Pathways scores a major victory in their bid to patent Comp 360, a proprietary...
-
June 20, 2022 Cybin Acquires Entheon’s DMT Trial, Numi’s Novamind Acq. Complete, Bad News for MindMed and MoreThis week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon;...
